ecancermedicalscience

Case Report

Re-challenge of immune checkpoint inhibitor pembrolizumab with concurrent tocilizumab after prior grade 3 pneumonitis

8 Dec 2023
Chitrakshi Nagpal, Sameer Rastogi, Shamim A Shamim, Sneha Prakash

Immune checkpoint inhibitors (ICIs) are associated with specific immune-related adverse events (irAEs) which are unique compared to cytotoxic chemotherapy. For life-threatening adverse events including grade 3 or more, permanent discontinuation of the ICIs is recommended, albeit without much robust evidence. Safe re-challenge of ICIs with concurrent immunosuppression has been reported with irAEs like gastrointestinal toxicity and arthritis. Here we present a case of a lady with undifferentiated pleomorphic sarcoma with programmed death ligand1 expression, who showed a complete response to pembrolizumab used as third-line therapy. However, it had to be stopped after 22 doses when the patient developed grade 3 pneumonitis. In view of progression off pembrolizumab, and lack of other effective alternatives, pembrolizumab was re-challenged with concurrent interleukin-6 (IL-6) blockade using tocilizumab. This was based on preliminary evidence on the role of IL-6 in mediating the irAEs, especially pneumonitis. The patient re-attained a complete response with pembrolizumab. There was no recurrence of the pneumonitis after rechallenging, and there was partial radiographic resolution of the ICI-interstitial lung disease after the combination therapy.

Related Articles

Johnblack K Kabukye, Alice B S Nono Djotsa, Adedayo Joseph, Charles Muya, Benda N Kithaka, Mishka K Cira, Leshia Hansen, Annet Nakaganda
Kamboji Sharanya, Lulu Abdul khader, Fathima Shahama Oliyath Vazhayil, Ghazal Tansir, Vaishnavi Vishwas, Simran Kaur, Sameer Rastogi, Ratna Sharma
Kofi Effah, Ethel Tekpor, Comfort Mawusi Wormenor, Joseph Emmanuel Amuah, Vida Kwawukume, Louisa Ademki Matey, Seyram Kemawor, Stephen Danyo, Esu Aku Catherine Morkli, Nana Owusu Mensah Essel, Emmanuel Timmy Donkoh, Patrick Kafui Akakpo